NEW YORK, NY--(Marketwired - Oct 30, 2013) - IntelliCell BioSciences, Inc. (
Mr. Herschman currently serves as President and CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial institutions seeking strategic consultation. In December 2006, Mr. Herschman was appointed as the independent compliance advisor to the board of directors of Siemens AG, a company with more than 400,000 employees. He is a member of the board of directors of the U.S. Chamber of Commerce Foundation, and advises the Chamber on corporate compliance issues.He began his career in intelligence and investigations in Europe as a special agent with U.S. Military Intelligence, specializing in counter-terrorism. After leaving the military, he moved to investigations of government misconduct and financial fraud for the New York State Attorney General's Office and the Office of the Mayor of New York City.
IntelliCell's Chairman and CEO, Dr. Steven Victor, stated, "Mr. Michael Herschman is an internationally recognized expert on matters relating to transparency, accountability, governance, financial compliance. His proven track record of success and previous board experience will provide invaluable council to IntelliCell as we navigate the complex capital markets. Mr. Herschman's knowledge in building world-renowned organizations as he has with Fairfax Group will provide a strong competitive advantage as we continue to establish ourselves as a leader within the regenerative medical industry. His strong belief in the company's growth potential and business value proposition is a testament to the strength of our strategy."
Since 2008, Mr. Herschman has been named every consecutive year to the Ethisphere Institute's list of the top 100 most influential people in business ethics worldwide. Michael Herschman has given hundreds of speeches throughout the world on issues related to transparency and accountability and has provided commentary on ABC, CBS, NBC, PBS, CNN, CNBC, MSNBC and the Fox News Channel as well as countless national radio shows. For five years he was the co-host of the Public Radio Law Show. He has been quoted and published in the Wall Street Journal, the New York Times, the New York Post, the Washington Post, USA Today, the Financial Times, the National Law Journal and other print media.
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. One of the revenue streams IntelliCell is pursuing is placing its labs into Hospitals and Ambulatory Surgical Centers. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.